Recs

1

What's Driving Abbott Labs Today

By | More Articles
October 20, 2012 | Comments (0)

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Today, Fool.com analysts David Williamson and Max Macaluso look at the three big events driving Abbott Labs today. Topping the list is the impressive results for its hepatitis C drug, which appears significantly more successful than Gilead's comparable drug and bodes well for the planned AbbVie spinoff. On the other hand, the company has had to discontinue phase 3 trials for its potential kidney disease and diabetes drug, and investors should keep an eye on the looming patent cliff.

The biotech space is full of ebbs and flows in company fortunes, and if you don't know how to play the sector, you can get burned. See more in the following video.

The best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

David Williamson owns shares of Johnson & Johnson and Pfizer. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 2067190, ~/Articles/ArticleHandler.aspx, 5/24/2013 5:24:57 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 8 hours ago Sponsored by:
DOW 15,294.50 -12.67 -0.08%
S&P 500 1,650.51 -4.84 -0.29%
NASD 3,459.42 -3.88 -0.11%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

5/23/2013 4:00 PM
MRK $47.33 Up +0.62 +1.33%
Merck & Co., Inc. CAPS Rating: ****
PFE $29.11 Down -0.19 -0.65%
Pfizer CAPS Rating: ****
JNJ $87.21 Down -0.59 -0.67%
Johnson & Johnson CAPS Rating: *****
ABT $37.48 Down -0.24 -0.64%
Abbott Laboratorie… CAPS Rating: *****
GILD $55.48 Down -0.45 -0.80%
Gilead Sciences CAPS Rating: ****

Advertisement